$24.24
2.80% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US4579852082
Symbol
IART

Integra LifeSciences Holdings Corporation Stock price

$24.24
+5.29 27.92% 1M
-4.07 14.38% 6M
-19.31 44.34% YTD
-14.44 37.33% 1Y
-43.22 64.07% 3Y
-36.52 60.11% 5Y
+2.21 10.02% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.66 2.80%
ISIN
US4579852082
Symbol
IART
Sector

Key metrics

Market capitalization $1.87b
Enterprise Value $3.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 94.17
EV/Sales (TTM) EV/Sales 2.29
P/S ratio (TTM) P/S ratio 1.20
P/B ratio (TTM) P/B ratio 1.23
Revenue growth (TTM) Revenue growth 1.45%
Revenue (TTM) Revenue $1.56b
EBIT (operating result TTM) EBIT $155.27m
Free Cash Flow (TTM) Free Cash Flow $38.04m
Cash position $277.60m
EPS (TTM) EPS $-0.09
P/E forward 39.90
P/S forward 1.16
EV/Sales forward 2.22
Short interest 7.79%
Show more

Is Integra LifeSciences Holdings Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Integra LifeSciences Holdings Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

3x Buy
21%
7x Hold
50%
4x Sell
29%

Analyst Opinions

14 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

Buy
21%
Hold
50%
Sell
29%

Financial data from Integra LifeSciences Holdings Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,565 1,565
1% 1%
100%
- Direct Costs 685 685
8% 8%
44%
880 880
3% 3%
56%
- Selling and Administrative Expenses 500 500
2% 2%
32%
- Research and Development Expense 91 91
2% 2%
6%
289 289
6% 6%
18%
- Depreciation and Amortization 134 134
8% 8%
9%
EBIT (Operating Income) EBIT 155 155
16% 16%
10%
Net Profit -6.54 -6.54
106% 106%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Integra LifeSciences Holdings Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Integra LifeSciences Holdings Corporation Stock News

Neutral
GlobeNewsWire
13 days ago
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa su...
Neutral
Seeking Alpha
22 days ago
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference Call Participants Steven Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Kristen Stewart - C.L. King Robbie Marcus - JPMorgan...
Neutral
GlobeNewsWire
22 days ago
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024.
More Integra LifeSciences Holdings Corporation News

Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Head office United States
CEO Jan Witte
Employees 5,329
Founded 1989
Website www.integralife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today